Legend Biotech Corp (LEGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Legend Biotech Corp (LEGN) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($28.80 Million) by net assets ($1.01 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Legend Biotech Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Legend Biotech Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read LEGN total liabilities for a breakdown of total debt and financial obligations.
Legend Biotech Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Legend Biotech Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enerjisa Enerji AS
IS:ENJSA
|
0.063x |
|
Beijing BDStar Navigation Co Ltd
SHE:002151
|
0.001x |
|
KB Home
NYSE:KBH
|
0.079x |
|
Beijing GeoEnviron Engineering
SHG:603588
|
0.003x |
|
Global Health Limited
NSE:MEDANTA
|
0.024x |
|
Navan, Inc. Class A Common Stock
NASDAQ:NAVN
|
0.029x |
|
Towne Bank
NASDAQ:TOWN
|
0.048x |
|
Ningxia Orient Tantalum Industry Co Ltd
SHE:000962
|
-0.065x |
Annual Cash Flow Conversion Efficiency for Legend Biotech Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of Legend Biotech Corp from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see LEGN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.04 Billion | $-144.03 Million | -0.138x | +55.96% |
| 2023-12-31 | $1.25 Billion | $-393.28 Million | -0.314x | -16.22% |
| 2022-12-31 | $744.31 Million | $-201.28 Million | -0.270x | -4.37% |
| 2021-12-31 | $765.94 Million | $-198.47 Million | -0.259x | +30.31% |
| 2020-12-31 | $599.82 Million | $-223.00 Million | -0.372x | -154.99% |
| 2019-12-31 | $-122.87 Million | $-83.06 Million | 0.676x | -98.10% |
| 2018-12-31 | $8.65 Million | $307.68 Million | 35.574x | +18315.35% |
| 2017-12-31 | $12.17 Million | $-2.38 Million | -0.195x | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more